Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

In den letzten Wochen hat der europäische Markt Resilienz gezeigt, da der STOXX Europe 600 Index um 0,14% zulegt. Investoren beobachten eng die Entwicklungen in der globalen Geopolitik und wirtschaftlichen Indikatoren wie der Arbeitslosenquote Deutschlands und dem BIP-Wachstum Italiens. Kleine Aktienkapitalien ziehen weiterhin Aufmerksamkeit auf sich, da sie während der Wirtschaftsrecovery durch ihre Agilität und Wachstumsaussichten überdurchschnittliche Renditen erzielen können. Ein guter Aktienkauf in dieser Umgebung kombiniert starke Grundlagen mit der Fähigkeit, sich an sich verändernde geopolitische Landschaften anzupassen, was Unternehmen wie Société Fermière du Casino Municipal de Cannes als interessante Kandidaten für die Erforschung unter den europäischen Small-Cap-Gemsen erscheinen lässt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Artikel beschreibt die Ergebnisse von Eckert & Ziegler SE für das Quartal 2026. Die Gesellschaft meldete einen Umsatzanstieg um 7% und ein starkes Wachstum im medizinischen Bereich, der um über 20% stieg. Der CEO erwähnt die Optimismus für den nuklearen Medizinbereich mit einer 15-prozentigen CAGR bis 2030. Die Gesellschaft hat eine starke Cash-Position von 120 Millionen Euro und ist offen für strategische Investitionen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Last week saw the newest full-year earnings release from Eckert & Ziegler SE (ETR:EUZ), an important milestone in the company's journey to build a stronger business. It looks like a pretty bad result, all things considered. Although revenues of €312m were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 29% to hit €0.78 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.XTRA:EUZ Earnings and Revenue Growth March 30th 2026

Taking into account the latest results, the current consensus from Eckert & Ziegler's three analysts is for revenues of €322.5m in 2026. This would reflect a credible 3.4% increase on its revenue over the past 12 months. Per-share earnings are expected to increase 7.5% to €0.84. Yet prior to the latest earnings, the analysts had been anticipated revenues of €341.9m and earnings per share (EPS) of €0.88 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the minor downgrade to earnings per share expectations.

View our latest analysis for Eckert & Ziegler

Despite the cuts to forecast earnings, there was no real change to the €22.43 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Eckert & Ziegler at €24.00 per share, while the most bearish prices it at €20.30. This is a very narrow spread of estimates, implying either that Eckert & Ziegler is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Eckert & Ziegler's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 3.4% growth on an annualised basis. This is compared to a historical growth rate of 13% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 5.5% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Eckert & Ziegler.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Eckert & Ziegler analysts - going out to 2028, and you can see them free on our platform here.

We also provide an overview of the Eckert & Ziegler Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Molecular Partners

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026 Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026 Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range of isotopes, including 225Ac Phase 2 investigator-initiated randomized trial of tumor-localized CD40 agonist MP0317 combined with standard-of-care for cholangiocarcinoma; patient dosing ongoing Phase 1/2a trial of multi-specific T cell engager MP0533 for patients with AML continues with update on clinical development path in H1 2026 Strong financial position with cash including short-term time deposits, of CHF 93.1 million, providing runway until 2028

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LRMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its corporate highlights and audited financial results for the full year 2025, as well as the publication of its 2025 Annual Report.

"We are making significant progress in targeted alpha radiotherapy, as our first Radio-DARPin candidate, MP0712 targeting DLL3, enters clinical development. Early imaging and dosimetry results support the ongoing Phase 1/2a study for MP0712, which aims to address critical needs in lung cancer treatment,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. He added: “We are strengthening our expertise with a strong scientific advisory board, chaired by Prof. Ken Herrmann, to support our growing Radio-DARPin pipeline, with MP0726 moving towards imaging and new candidates being selected. Our solid finances position us well for future growth.”

Research & Development Highlights

MP0712 & Radio-DARPin Pipeline

The MP0712 Phase 1/2a trial has started (ClinicalTrials.gov: NCT07278479) and recruitment is open. MP0712 is the Company’s lead Radio-DARPin Therapy (RDT) targeting the tumor-associated protein delta-like ligand 3 (DLL3) and carrying the therapeutic payload 212Pb. It is being developed with Molecular Partners’ strategic partner Orano Med, a pioneer in targeted alpha therapy, for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The Phase 1/2a study is a multi-center study in the US, with the objectives to assess safety and determine a recommended Phase 2 dose for MP0712. The study contains a pre-treatment imaging and dosimetry step with 203Pb-labeled MP0712. The Company expects initial clinical data from this study in 2026.

Story Continues

Molecular Partners and the NuMeRI team presented first patient imaging and dosimetry data on MP0712 at the 8th Theranostics World Congress (TWC) in January 2026. The data from five evaluable patients with various DLL3-expressing cancers, including small cell lung, urothelial, and other neuroendocrine cancers, were generated with MP0712 carrying the diagnostic isotope 203Pb under the leadership of Dr. Mike Sathekge as part of a Named Patient Access Program under the legal framework for compassionate care in South Africa (also referred to as Section 21 of the Medicines and Related Substances Act). The images show specific uptake as well as robust accumulation of MP0712 in tumor lesions, with limited uptake in healthy tissues, as intended, confirming the initial data on MP0712 presented at the Targeted Radiopharmaceuticals (TRP) Summit Europe 2025. MP0712 is half-life engineered to promote tumor uptake over time via the DLL3 internalization and replenishment mechanism. The biodistribution and dosimetry extrapolations are supportive of the Phase 1/2a study design and of the clinical development plans of MP0712 carrying the therapeutic isotope 212Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers.

The Company’s second RDT program MP0726, co-developed with Orano Med, targets mesothelin (MSLN), a tumor target overexpressed across several cancers with high unmet need, such as ovarian cancer. Molecular Partners has developed Radio-DARPins able to selectively bind to membrane-bound MSLN without being impacted by shed MSLN – a mechanism which has hampered the development of other MSLN-targeting therapeutics. The Company presented preclinical data on MP0726 at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The Company is planning to progress several Radio-DARPin programs towards first-in-human imaging, including MP0726.

For its growing Radio-DARPin pipeline and based on the first-in-human Radio-DARPin data presented at TWC 2026 indicating that Radio-DARPins may be suitable vectors for alpha-emitting isotopes, including 212Pb and also the longer-lived 225Ac, Molecular Partners is evaluating various radio-nuclides moving forward to tailor Radio-DARPin candidates to patient needs – matching vector and isotope properties with target and disease biology. Molecular Partners entered a non-exclusive development agreement with Eckert & Ziegler for targeted alpha radio-therapeutics, thereby enabling the potential of Radio-DARPins for a range of therapeutic isotopes, including 225Ac, and advancing the Company's wholly owned pipeline. The Company plans to present pre-clinical data on Radio-DARPins suitability with multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China.

In December 2025 Molecular Partners announced the formation of a scientific advisory board (SAB) to accelerate the development of its targeted radiotherapeutics. The SAB, chaired by well-known nuclear medicine expert Prof. Ken Herrmann, will be instrumental in guiding Molecular Partners strategic direction as it transitions and evolves from early clinical validation to full clinical development of its targeted alpha radiotherapies.

Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions with the potential to unlock a broad range of solid tumor targets for radiopharmaceuticals.

MP0317 (tumor-localized CD40 agonist)

An investigator-initiated, proof-of-concept Phase 2 study of MP0317 combined with standard-of-care (SoC) for the treatment of patients with advanced cholangiocarcinoma is now open with two sites activated (NCT07036380) and patient dosing ongoing. The study is a randomized, multicenter study in France and aims to recruit 75 patients (with a 2to1 design, including 50 patients in the experimental arm, and 25 in the control arm). The objective of the study is to assess the clinical benefit of MP0317 combined with SoC comprising the immunotherapy durvalumab, an anti-PD-L1 checkpoint inhibitor, plus gemcitabine-cisplatin-based chemotherapy, compared to SoC alone. The tumor microenvironment (TME) is known to play a crucial role in cholangiocarcinoma development and treatment resistance. MP0317 is hypothesized to lead to immune-mediated reshaping of the TME, thereby improving the 12-month progression-free survival rate of patients compared to those treated with SoC only.

MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein (FAP), which is expressed in high amounts in the stroma of various solid tumors, including cholangiocarcinoma. The Company completed a Phase 1 dose-escalation study of MP0317 in patients with advanced solid tumors in 2024 (NCT05098405; 46 patients treated across 9 dose levels). Comprehensive biomarker analyses from this trial showed tumor-localized CD40 activation and remodeling of the TME. CD40 is an attractive target for cancer immunotherapy due to its strong immune-stimulatory activity. Molecular Partners believes that MP0317’s tumor-localized approach has the potential to deliver superior efficacy with fewer side effects compared to systemic CD40 agonists.

MP0533 (multispecific T cell engager)

MP0533 is currently being evaluated in a Phase 1/2a clinical trial for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome/AML (NCT05673057).

Data presented at the 2025 American Society of Hematology (ASH) Annual Meeting showed that densified dosing appears tolerable, and leads to markedly improved serum exposure in cycle 1, along with antitumor activity, in particular in patients with low bone marrow blast count at baseline. Cohort 10 is currently dosing patients and an update on this study is expected in H1 2026.

Molecular Partners plans to support the exploration of MP0533 in combination, both in patients with relapsed/refractory disease as well as in front-line, and has been approached by several consortia expressing interest in conducting such studies. The Company is actively engaging with key opinion leaders and regulators to shape the next phase of development, and anticipates updating the clinical plan for MP0533 in H1 2026.

MP0533 is a novel tetra-specific T cell-engaging DARPin designed for selective and broad killing of AML cells in a mutation-agnostic manner. MP0533’s mode of action enables T cell-mediated killing of AML cells – which commonly co-express at least two of the three targeted antigens (CD33, CD123, CD70) – while preserving a therapeutic window that minimizes damage to healthy cells, which normally express one or none of the targets.

Switch-DARPin Platform (next-generation immune cell engagers)

Molecular Partners designed a logic-gated Switch-DARPin T-cell engager (TCE) to achieve conditional tumor-localized immune activation targeting MSLN and epithelial cell adhesion molecule (EpCAM), which are highly co-expressed in ovarian cancer and other solid tumors. The Switch-DARPin TCE is designed to unmask the CD3-engaging DARPin (“Switch” on) and to activate T cells only upon binding to both MSLN and EpCAM. Co-engagement of CD2 leads to sustained T-cell activation and cytotoxic capacity, enabling the development of potent TCEs with an improved therapeutic window. This Switch-DARPin is half-life extended through a Fc domain, which broadens the Company’s capabilities in half-life engineering modalities.

Based on the encouraging pre-clinical data presented at the 2025 Annual Meetings of the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC), the Company intends to nominate a lead Switch-DARPin candidate for development in H1 2026 and will provide an update on the program at AACR 2026.

Corporate Governance & Leadership Highlights

Molecular Partners appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer (CSO) and member of its Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies.

In 2025 Molecular Partners performed a strategic review of its operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets.

In April 2025, all motions proposed by the Board of Directors at the Annual General Meeting were approved by the shareholders of the Company by a wide majority.

2025 Financial Highlights

In the financial year ended December 31, 2025, Molecular Partners recognized no revenue (2024: CHF 5.0 million) and incurred total operating expenses of CHF 58.1 million (2024: CHF 66.2 million). This led to an operating loss of CHF 58.1 million for 2025 (2024: Operating loss of CHF 61.2 million).

The net financial loss recorded in 2025 was CHF 3.5 million, compared to a net financial gain of CHF 7.2 million in 2024. This resulted in a 2025 net loss of CHF 61.7 million (2024: Net result of CHF 54.0 million).

The net cash used in operating activities in 2025 was CHF 51.3 million (2024: Net cash used in operating activities CHF 59.2 million). Including short-term time deposits, the cash and cash equivalents position decreased by CHF 56.3 million as compared to year-end 2024, to CHF 93.1 million as of December 31, 2025 (December 31, 2024: CHF 149.4 million). Total shareholders’ equity stood at CHF 80.3 million as of December 31, 2025, a decrease of CHF 61.3 million (December 31, 2024: CHF 141.6 million).

The Company's cash and cash equivalents and short-term time deposits were CHF 93.1 million as of December 31, 2025, and based on current operating assumptions, will be sufficient to fund its operating expenses and capital expenditure requirements until 2028.

The Company's balance sheet remained debt-free as of December 31, 2025. As of December 31, 2025, the Company employed 134.0 FTE (full-time equivalents). About 81% of the employees are employed in R&D-related functions.

Key figures as of December 31, 2025

Key Financials (CHF million, except per share, FTE data) FY 2025 FY 2024 Change Total revenues and other income — 5.0 (5.0 ) R&D expenses (40.2 ) (48.6 ) 8.4 SG&A expenses (15.2 ) (17.6 ) 2.4 Restructuring expenses (2.7 ) — (2.7 ) Total operating expenses (incl depr. & amort.) (58.1 ) (66.2 ) 7.9 Operating result (58.1 ) (61.2 ) 3.1 Net finance result (3.5 ) 7.2 (10.7 ) Net result (61.7 ) (54.0 ) (7.6 ) Basic net result per share (in CHF) (1.65 ) (1.59 ) 0.30 Net cash (used in) from operating activities (51.3 ) (59.2 ) 7.9 Cash & cash equivalents (incl. short-term time deposits) 93.1 149.4 (56.3 ) Total shareholders’ equity 80.3 141.6 (61.3 ) Number of total FTE 134.0 158.5 (24.5 )

Financial outlook 2026

For the full year 2026, at constant exchange rates, the Company expects total operating expenses of CHF 45-55 million, of which around CHF 6 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.

Documentation

This press release, the Company's Annual Report on Form 20-F for the year ended December 31, 2025 to be filed with the U.S. Securities and Exchange Commission (SEC), and the Company's annual report 2025 will be made available through www.molecularpartners.com under the investor section after 10.00 pm CET (4.00 pm EST) on March 12, 2026.

Financial calendar

April 14, 2026 Annual General Meeting May 12, 2026 Interim Management Statement Q1 2026 August 25, 2026 Half-year results 2026 (unaudited) October 29, 2026 Interim Management Statement Q3 2026

The latest timing of the above events can always be viewed on the investor section of the website.

About DARPin Therapeutics DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. seth.lewis@molecularpartners.com Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland laura.jeanbart@molecularpartners.com Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of Molecular Partners’ SAB and new CSO; the expected benefits of the strategic review; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate", “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Molecular Partners

Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it has entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics.

"We are pleased to work with Eckert & Ziegler, a global leader in radiopharmaceutical manufacturing. This agreement will expand the potential of Radio-DARPins as vectors for precise delivery of therapeutic alpha-emitting isotopes to tumors, now including Actinium-225, in addition to Lead-212 through our long-term strategic partnership with Orano Med,” said Alexander Zürcher, COO of Molecular Partners. He added: “The promise of Radio-DARPins is underlined by the progress of our lead candidate MP0712, targeting DLL3, having just opened the Phase 1/2a trial for the treatment of patients with small cell lung cancer (SCLC)”.

Under the non-exclusive agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 (225Ac) and Lutetium-177 (177Lu) payloads. The development agreement will leverage Eckert & Ziegler’s state-of-the-art laboratories, including its newly established Alpha Laboratory in Berlin, Germany, dedicated exclusively to work with alpha emitters.

For its growing Radio-DARPin pipeline, Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs – matching vector and isotope properties with target and disease biology. The Company plans to present pre-clinical data on Radio-DARPins’ suitability with multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China.

Eckert & Ziegler is a globally leading specialist for isotope-related components in nuclear medicine and radiation therapy, offering a broad range of services and products from early development work to contract manufacturing and distribution.

“Supporting highly innovative companies such as Molecular Partners in developing their promising technology platforms is a key objective of our group,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Bringing together our expertise in isotopes, radiochemistry and development infrastructure with our partners' innovations will enable patients worldwide to benefit from new treatments in the future.”

Story Continues

About Radio-DARPins

Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

About DARPin Therapeutics DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact: Molecular Partners Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. seth.lewis@molecularpartners.com Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland laura.jeanbart@molecularpartners.com Tel: +41 44 575 19 35

Eckert & Ziegler SE Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations jan.schoepflin@ezag.de / karolin.riehle@ezag.de Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential that Molecular Partners’ product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners’ actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Eckert & Ziegler SE (ETR:EUZ), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the XTRA over the last few months, increasing to €16.85 at one point, and dropping to the lows of €14.37. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Eckert & Ziegler's current trading price of €14.96 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Eckert & Ziegler’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What's The Opportunity In Eckert & Ziegler?

Eckert & Ziegler is currently expensive based on our price multiple model, where we look at the company's price-to-earnings ratio in comparison to the industry average. We’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 23.04x is currently well-above the industry average of 17.62x, meaning that it is trading at a more expensive price relative to its peers. But, is there another opportunity to buy low in the future? Given that Eckert & Ziegler’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

View our latest analysis for Eckert & Ziegler

Can we expect growth from Eckert & Ziegler?XTRA:EUZ Earnings and Revenue Growth February 16th 2026

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Eckert & Ziegler's earnings over the next few years are expected to increase by 48%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has well and truly priced in EUZ’s positive outlook, with shares trading above industry price multiples. However, this brings up another question – is now the right time to sell? If you believe EUZ should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Story Continues

Are you a potential investor? If you’ve been keeping an eye on EUZ for a while, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for EUZ, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Diving deeper into the forecasts for Eckert & Ziegler mentioned earlier will help you understand how analysts view the stock going forward. So feel free to check out our free graph representing analyst forecasts.

If you are no longer interested in Eckert & Ziegler, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

As we enter January 2026, the European markets are navigating a landscape marked by geopolitical uncertainty and modest economic growth, with the STOXX Europe 600 Index recently ending lower amid renewed trade tensions. Despite these challenges, optimism in business outlooks and positive PMI readings suggest that there are still opportunities for discerning investors to uncover potential in lesser-known stocks. In this environment, identifying a good stock often involves looking for companies with strong fundamentals that can weather volatility while capitalizing on emerging market trends.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Name Debt To Equity Revenue Growth Earnings Growth Health Rating Bijou Brigitte modische Accessoires NA 10.79% 37.31% ★★★★★★ Intellego Technologies 5.42% 70.25% 79.14% ★★★★★★ Caisse Régionale de Crédit Agricole Mutuel Brie Picardie Société coopérative 37.61% 3.36% 6.34% ★★★★★★ Arendals Fossekompani 26.72% 2.84% 7.78% ★★★★★★ Evergent Investments 3.63% 11.51% 22.05% ★★★★★☆ Grenobloise d'Electronique et d'Automatismes Société Anonyme 0.01% 7.01% -1.81% ★★★★★☆ Dn Agrar Group NA 29.02% 36.03% ★★★★★☆ Inversiones Doalca SOCIMI 13.10% 6.72% 3.11% ★★★★★☆ MCH Group 126.04% 19.05% 60.90% ★★★★☆☆ Alantra Partners 11.36% -6.39% -33.69% ★★★★☆☆

Click here to see the full list of 295 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Let's review some notable picks from our screened stocks.

Arteche Lantegi Elkartea

Simply Wall St Value Rating: ★★★★★☆

Overview: Arteche Lantegi Elkartea, S.A. specializes in the design, manufacture, integration, and supply of electrical equipment and solutions with an emphasis on renewable energy and smart grids both in Spain and internationally, with a market cap of approximately €1.28 billion.

Operations: Arteche generates revenue primarily from three segments: Systems Measurement and Monitoring (€352.38 million), Network Reliability (€46.51 million), and Automation of Transmission and Distribution Networks (€79.77 million).

Arteche Lantegi Elkartea, a player in the electrical sector, is navigating a landscape ripe with opportunities due to electrification and renewable energy trends. The company’s debt-to-equity ratio has impressively reduced from 333% to 134.2% over five years, indicating improved financial leverage. However, its net debt to equity remains high at 41.3%. Arteche's earnings growth of 120.6% last year outpaced the industry average of 10.3%, showcasing robust performance despite challenges like low R&D spending and supply chain issues. With EBIT covering interest payments by 9.4 times, Arteche demonstrates strong profit coverage on its debts.

Story Continues

Arteche Lantegi Elkartea's growth hinges on reducing its PE ratio amid rising costs. Click here to explore the full narrative on Arteche's strategic challenges and opportunities.BME:ART Debt to Equity as at Jan 2026

Eckert & Ziegler

Simply Wall St Value Rating: ★★★★★☆

Overview: Eckert & Ziegler SE is a global manufacturer and supplier of isotope technology components, with a market capitalization of approximately €1.01 billion.

Operations: Eckert & Ziegler SE generates revenue primarily through its Medical and Isotopes Products segments, contributing approximately €163.74 million and €151.65 million, respectively. The company's financial performance is impacted by segment adjustments and eliminations totaling around -€10.92 million.

Eckert & Ziegler, a nimble player in the medical equipment sector, is trading at a significant discount of 50.2% below its estimated fair value. The company's earnings growth over the past year reached 13.1%, outpacing the industry average and showcasing its robust performance. With net income for Q3 2025 at €8.46 million, up from €5.35 million in the same period last year, it highlights strong financial health despite a slight dip in diluted EPS to €0.13 from €0.15 previously. A recent supply agreement with SK Biopharmaceuticals further underscores its strategic expansion in radiopharmaceuticals globally.

Dive into the specifics of Eckert & Ziegler here with our thorough health report. Evaluate Eckert & Ziegler's historical performance by accessing our past performance report.XTRA:EUZ Debt to Equity as at Jan 2026

MBB

Simply Wall St Value Rating: ★★★★★★

Overview: MBB SE, along with its subsidiaries, focuses on acquiring and managing medium-sized companies mainly in the technology and engineering sectors both in Germany and internationally, with a market capitalization of approximately €1.14 billion.

Operations: MBB SE generates revenue primarily from three segments: Service & Infrastructure (€781.36 million), Technological Applications (€299.66 million), and Consumer Goods (€85.49 million).

MBB, a dynamic player in the European market, is making waves with its impressive earnings growth of 101.5% over the past year, outpacing the industrial sector's average. The company's debt-to-equity ratio has improved significantly from 13.7 to 4.5 over five years, showcasing prudent financial management. With a strategic focus on high-margin automation and software solutions alongside value-accretive M&A activities, MBB aims to bolster profitability despite challenges in volatile markets like automotive and public sectors. The company is trading at 36.7% below its estimated fair value, indicating potential upside for investors seeking opportunities in this evolving space.

MBB's robust order backlog and strategic international expansion provide diversification against domestic economic slowdowns. Click here to explore the full narrative on MBB's investment potential.XTRA:MBB Debt to Equity as at Jan 2026

Turning Ideas Into Actions

Explore the 295 names from our European Undiscovered Gems With Strong Fundamentals screener here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Want To Explore Some Alternatives?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:ART XTRA:EUZ and XTRA:MBB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

BERLIN – 12. Januar 2026 (NEWMEDIAWIRE) – Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) wird am Mittwoch, den 14. Januar 2026, auf der 44. Jahreshauptkonferenz der J.P. Morgan Healthcare Conference im Westin St. Francis in San Francisco, Kalifornien, USA, teilnehmen. CEO Harald Hasselmann wird das Unternehmen um 17:15 PST präsentieren.

Die Präsentation wird als Audio-Live-Stream auf der Firmenwebsite verfügbar sein: https://www.ezag.com/investors/presentations/ Die Aufzeichnung wird nach dem Event für etwa 30 Tage verfügbar sein.

Über Eckert & Ziegler: Eckert & Ziegler SE, mit über 1.000 Mitarbeitern, ist ein führender Spezialist für isotopsbezogene Komponenten in der Nuklearmedizin und Strahlentherapie. Das Unternehmen bietet eine breite Palette von Dienstleistungen und Produkten für die Radiopharmaceutik-Industrie, von der frühen Entwicklungsarbeit bis hin zu Auftragsfertigung und Vertrieb. Eckert & Ziegler-Aktien (ISIN DE0005659700) sind im TecDAX Index der Deutschen Börse gelistet.

Wichtigste Kontaktinformationen: Eckert & Ziegler SE, Karolin Riehle, Investor Relations Robert-Rossle-Str. 10, 13125 Berlin, Deutschland Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Anmerkungen:

• I’ve used a clear and straightforward German translation style.
• I’ve included the key information and contact details.

Would you like me to adjust anything or perhaps create a slightly different version (e.g., a shorter summary)?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Key Insights

Eckert & Ziegler's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 8 shareholders own 50% of the company 30% of Eckert & Ziegler is held by Institutions

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

A look at the shareholders of Eckert & Ziegler SE (ETR:EUZ) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 35% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

As a result, retail investors were the biggest beneficiaries of last week’s 8.7% gain.

Let's take a closer look to see what the different types of shareholders can tell us about Eckert & Ziegler.

View our latest analysis for Eckert & Ziegler XTRA:EUZ Ownership Breakdown January 10th 2026

What Does The Institutional Ownership Tell Us About Eckert & Ziegler?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Eckert & Ziegler does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Eckert & Ziegler's earnings history below. Of course, the future is what really matters.XTRA:EUZ Earnings and Revenue Growth January 10th 2026

Hedge funds don't have many shares in Eckert & Ziegler. Looking at our data, we can see that the largest shareholder is Eckert Wagniskapital und Frühphasenfinanzierung GmbH with 32% of shares outstanding. Norges Bank Investment Management is the second largest shareholder owning 3.4% of common stock, and Morgan Stanley holds about 3.1% of the company stock.

We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Story Continues

Insider Ownership Of Eckert & Ziegler

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our most recent data indicates that insiders own less than 1% of Eckert & Ziegler SE. Keep in mind that it's a big company, and the insiders own €196 worth of shares. The absolute value might be more important than the proportional share. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

General Public Ownership

With a 35% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Eckert & Ziegler. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 32%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important.

Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.

Ultimately the future is most important. You can access this freereport on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

As European markets show signs of steady economic growth, with the STOXX Europe 600 Index rising by 1.60% and key indices like Italy's FTSE MIB and the UK's FTSE 100 posting gains, investors are increasingly optimistic about opportunities in this region. In this environment of looser monetary policy and stable growth forecasts, identifying stocks with strong fundamentals and innovative potential becomes crucial for those looking to capitalize on hidden opportunities within Europe's diverse market landscape.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Name Debt To Equity Revenue Growth Earnings Growth Health Rating Dekpol 61.42% 9.03% 14.54% ★★★★★★ KABE Group AB (publ.) 3.82% 3.46% 5.42% ★★★★★☆ Grenobloise d'Electronique et d'Automatismes Société Anonyme 0.01% 7.01% -1.81% ★★★★★☆ Freetrailer Group 38.17% 23.13% 31.09% ★★★★★☆ Dn Agrar Group NA 29.02% 36.03% ★★★★★☆ Mangold Fondkommission NA -6.00% -42.55% ★★★★★☆ VNV Global 15.38% -18.33% -18.19% ★★★★★☆ ABG Sundal Collier Holding 35.58% -7.59% -18.30% ★★★★☆☆ Alantra Partners 11.36% -6.39% -33.69% ★★★★☆☆ MCH Group 126.04% 19.05% 60.90% ★★★★☆☆

Click here to see the full list of 306 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

RCS MediaGroup

Simply Wall St Value Rating: ★★★★★☆

Overview: RCS MediaGroup S.p.A. is a multimedia publishing company operating in Italy, Spain, and internationally, with a market capitalization of approximately €496.17 million.

Operations: RCS MediaGroup generates revenue primarily from segments including Newspapers Italy (€358.60 million), Advertising and Sport (€280.10 million), Unidad Editorial (€208.80 million), Magazines Italy (€63.30 million), and Corporate and Other Activities (€80.50 million).

RCS MediaGroup, a smaller player in the media sector, showcases some compelling financial traits. Its interest payments are well covered by EBIT at 22.2 times, indicating solid financial health. Over the past five years, debt to equity has significantly decreased from 51.1% to 7.4%, reflecting prudent management of liabilities. Despite recent shareholder dilution and a slight dip in sales to €234 million for the nine months ending September 2025, RCS's earnings growth of 0.3% outpaced the industry's -2.3%. Trading at a substantial discount of 73% below estimated fair value suggests potential upside for investors seeking undervalued opportunities in Europe.

Click here and access our complete health analysis report to understand the dynamics of RCS MediaGroup. Learn about RCS MediaGroup's historical performance.

Story Continues

BIT:RCS Debt to Equity as at Dec 2025

ASBISc Enterprises

Simply Wall St Value Rating: ★★★★☆☆

Overview: ASBISc Enterprises Plc is a global trader and distributor of computer hardware and software, operating in regions including the Former Soviet Union, Central Eastern Europe, Western Europe, the Middle East, Africa, and beyond; it has a market cap of PLN1.75 billion.

Operations: ASBISc Enterprises generates revenue primarily from its role as a distributor of IT products, with reported sales of $3.54 billion. The company's financial performance is influenced by its gross profit margin, which provides insight into profitability trends over time.

ASBISc Enterprises, a smaller player in the electronics distribution sector, has demonstrated robust earnings growth of 75.9% over the past year, outpacing its industry peers. Despite a high net debt to equity ratio of 67.7%, their interest payments are well covered with an EBIT coverage of 4.3x. The company is trading at approximately 13.7% below its estimated fair value, suggesting potential undervaluation. Recent financial results show Q3 sales at US$929 million and net income at US$11.85 million, reflecting strong performance compared to last year’s figures and signaling positive momentum moving forward with revenue guidance indicating continued growth.

Unlock comprehensive insights into our analysis of ASBISc Enterprises stock in this health report. Understand ASBISc Enterprises' track record by examining our Past report.WSE:ASB Earnings and Revenue Growth as at Dec 2025

Eckert & Ziegler

Simply Wall St Value Rating: ★★★★★☆

Overview: Eckert & Ziegler SE is a company that specializes in manufacturing and selling isotope technology components globally, with a market capitalization of approximately €936.73 million.

Operations: Eckert & Ziegler SE generates revenue primarily from two segments: Medical (€163.74 million) and Isotope Products (€151.65 million). The company faces a revenue reduction due to eliminations amounting to -€10.92 million.

Eckert & Ziegler, a nimble player in the medical equipment sector, shows promise with its earnings growing 13% last year, outpacing industry averages. The company's debt to equity ratio has risen from 0.01% to 6.4% over five years, yet it holds more cash than total debt and boasts strong interest coverage at 61 times EBIT. Recent deals like supplying Actinium-225 to SK Biopharmaceuticals underline its strategic growth moves in radiopharmaceuticals. With sales forecasted at €320 million for 2025 and trading significantly below estimated fair value, Eckert & Ziegler presents an intriguing opportunity for investors seeking growth potential.

Dive into the specifics of Eckert & Ziegler here with our thorough health report. Explore historical data to track Eckert & Ziegler's performance over time in our Past section.XTRA:EUZ Earnings and Revenue Growth as at Dec 2025

Summing It All Up

Dive into all 306 of the European Undiscovered Gems With Strong Fundamentals we have identified here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Contemplating Other Strategies?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BIT:RCS WSE:ASB and XTRA:EUZ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments